Project Grant HT94252510342
Award Date
8/1/25
Completion Date
7/31/28
Dollars Obligated
$405K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Washington, DC 20010, USA
Similar Awards
The Defense Health Agency awarded a $777,659 Project Grant to Children's Research Institute to conduct research under the Military Medical Research and Development (CFDA 12.420) federal grant program. The project aims to use pro-resolution and restorative pharmacology approaches for Duchenne muscular dystrophy (DMD) therapy. The research will be performed at the Children's Research Institute in Washington, D.C. over a 3-year period from August 1, 2025 to July 31, 2028. As a leading pediatric...
This $563,484.00 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research conducted by Duke University to regulate skeletal muscle fibrosis in Duchenne muscular dystrophy. The two-year award, effective June 1, 2024 through May 31, 2026, will enable Duke University's research team to advance understanding and potential treatments for this debilitating neuromuscular disorder affecting military service members and...
The federal Project Grant award of $694,127 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the Northern California Institute for Research and Education, Inc. (NCIRE) for the project "IMPROVING CARDIAC AND DIAPHRAGM FUNCTION WITH BETA-3 ADRENERGIC RECEPTOR AGONIST IN DUCHENNE MUSCULAR DYSTROPHY". The grant, with a performance period from July 1, 2024 to June 30, 2026, will support research focused on investigating...
The University of Washington received a $617,221 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant funds research to advance the efficacy, longevity, and safety of gene editing therapies for Duchenne muscular dystrophy (DMD). The 2-year grant period runs from August 15, 2023 to August 14, 2025. As a leading research institution, the University of Washington has previously received federal funding to support a...
This federal Project Grant award of $345,664.00 from the Defense Health Agency, under the Military Medical Research and Development (CFDA 12.420) program, supports an advanced biomedical research initiative led by Royal Holloway University of London. The research project aims to develop an AAV-based microdystrophin gene therapy for Duchenne muscular dystrophy, with a focus on enhancing immune protection through capsid bioengineering. The award period spans from December 1, 2024 to November 30,...
This is a $538,218 federal Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant supports research conducted by the University of Texas Health Science Center at Houston (UTHealth) to study the role of ERR-alpha in skeletal muscle regeneration and functional recovery for Duchenne muscular dystrophy. The project aims to advance scientific understanding and develop potential treatments for this debilitating...
The Defense Health Agency awarded a $682,049 Project Grant to The Washington University under the Military Medical Research and Development program (CFDA 12.420). The grant will fund a research project from August 1, 2023 to July 31, 2026 to leverage a precision medicine platform to predict novel therapies for malignant peripheral nerve sheath tumors. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform military and public...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded a $1,708,955 project grant to the University of Washington to support a 3-year research study on "Enhanced Gene Therapy for DMD Using Larger Dystrophins and Lower Vector Doses". The grant, which commenced on September 15, 2023 and will be completed by September 14, 2026, aims to advance gene therapy approaches for the treatment of Duchenne muscular dystrophy (DMD). The University...
This $1,104,029 federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program will support research at the University of Florida to investigate MRI/MRS markers of skeletal muscle disease progression and vascular function in non-ambulatory individuals with Duchenne muscular dystrophy (DMD). The research will be conducted over a 3-year period from November 1, 2024 to October 31, 2027. The funding will enable the University of...
This federal Project Grant award of $657,945.00, funded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports research to predict the future quality of life for Duchenne muscular dystrophy (DMD) patients receiving different corticosteroid treatment regimens. The research will utilize serum proteome and steroid hormone profiling to develop a predictive model. The award was granted to Carleton University, a Canadian research institution,...